Products Rotateq™ + Comparator: Placebo
Rotateq™ + Comparator: Placebo Phase 3 Completed ⚡ Active Interest: 40/100
Jan 1, 2001 → Oct 1, 2004
About Rotateq™ + Comparator: Placebo Rotateq™ + Comparator: Placebo is a phase 3 stage product being developed by Merck for Rotavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00090233. Target conditions include Rotavirus Infections.
What happened to similar drugs? 1 of 12 similar drugs in Rotavirus Infections were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00090233 Phase 3 Completed Jan 1, 2001 Oct 1, 2004 Rotavirus Infections
Product Company Stage Hype Score Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™ Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered) Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 RotaTeq™ (V260) + DTP-IPV Merck Approved Comparator: RotaTeq + Comparator: Placebo + Comparator: RotaTeq + Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 3 V260 + Placebo to V260 + OPV + DTaP Merck Phase 3 rotavirus vaccine, live, oral, pentavalent + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa Merck Phase 3 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 Rotarix + RotaTeq Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified) Merck Phase 3